HomeCompareSKLUY vs ABBV

SKLUY vs ABBV: Dividend Comparison 2026

SKLUY yields 9.67% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SKLUY wins by $26775.22M in total portfolio value
10 years
SKLUY
SKLUY
● Live price
9.67%
Share price
$29.70
Annual div
$2.87
5Y div CAGR
88.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26775.32M
Annual income
$25,847,201,701.59
Full SKLUY calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — SKLUY vs ABBV

📍 SKLUY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSKLUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SKLUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SKLUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SKLUY
Annual income on $10K today (after 15% tax)
$822.15/yr
After 10yr DRIP, annual income (after tax)
$21,970,121,446.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, SKLUY beats the other by $21,970,099,920.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SKLUY + ABBV for your $10,000?

SKLUY: 50%ABBV: 50%
100% ABBV50/50100% SKLUY
Portfolio after 10yr
$13387.71M
Annual income
$12,923,613,513.18/yr
Blended yield
96.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SKLUY
No analyst data
Altman Z
7.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SKLUY buys
0
ABBV buys
0
No recent congressional trades found for SKLUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSKLUYABBV
Forward yield9.67%3.09%
Annual dividend / share$2.87$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR88.5%40.6%
Portfolio after 10y$26775.32M$103.7K
Annual income after 10y$25,847,201,701.59$25,324.79
Total dividends collected$26710.83M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SKLUY vs ABBV ($10,000, DRIP)

YearSKLUY PortfolioSKLUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,523$1,823.25$11,555$434.96+$968.00SKLUY
2$17,422$4,022.44$13,485$635.47+$3.9KSKLUY
3$28,500$9,858.39$15,933$937.67+$12.6KSKLUY
4$58,906$28,410.37$19,118$1,400.80+$39.8KSKLUY
5$166,475$103,445.71$23,384$2,125.24+$143.1KSKLUY
6$693,157$515,028.75$29,290$3,286.81+$663.9KSKLUY
7$4,519,505$3,777,827.26$37,776$5,205.38+$4.48MSKLUY
8$48,229,811$43,393,940.30$50,495$8,488.44+$48.18MSKLUY
9$867,401,483$815,795,586.12$70,497$14,346.44+$867.33MSKLUY
10$26,775,321,289$25,847,201,701.59$103,718$25,324.79+$26775.22MSKLUY

SKLUY vs ABBV: Complete Analysis 2026

SKLUYStock

Skellerup Holdings Limited designs, manufactures, markets, and distributes engineered products for various specialist industrial and agricultural applications. It operates through Agri and Industrial segments. The company offers food grade dairy rubberware, including milking liners, tubing products, accessories, filters, feeding teats, and other related agricultural products; rubber footwear for application in farm, as well as fire, forestry, and electrical distribution; dairy vacuum pumps; and dairy hygiene and livestock health management products, as well as mastitis prevention and mastitis detection equipment. It also provides sealing and waterproofing products for roofing, plumbing, and civil/underground applications; rubber and plastic products and components, such as pipe seals, diaphragms, washers, gaskets, customized rubber moldings, check valves, O-rings, and other components for use in automotive, industrial, infrastructural pipe, valve, and medical industries; high precision technical products for the automotive, flow control or water management, appliance, and industrial markets; and fabric reinforced diaphragms, and rubber metal seat valves and injector components, as well as injection-moulded and thermoformed engineered plastic products. In addition, the company offers EVA, PE, and various blended foams for marine, sports, leisure, orthotic/prosthetic, and construction applications; foam and soft material products for healthcare, electronics, construction, and comfort applications; and Flexiflo, a live wall system for installation in new and existing chutes, as well as silicone products. It operates primarily in New Zealand, Australia, North America, the United Kingdom, Ireland, rest of Europe, Asia, and internationally. Skellerup Holdings Limited was founded in 1910 and is based in Auckland, New Zealand.

Full SKLUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SKLUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SKLUY vs SCHDSKLUY vs JEPISKLUY vs OSKLUY vs KOSKLUY vs MAINSKLUY vs JNJSKLUY vs MRKSKLUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.